Overview

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis

Status:
Completed
Trial end date:
2020-01-28
Target enrollment:
Participant gender:
Summary
This study was conducted to evaluate the safety and tolerability of BOS-475 following single and repeat topical administration to healthy participants (Part A), and to evaluate the safety and tolerability of 42-day repeat topical administration of BOS-475 to participants with plaque psoriasis (Part B).
Phase:
Phase 1
Details
Lead Sponsor:
Boston Pharmaceuticals